. 2022 Jul 21;12:12477. doi: 10.1038/s41598-022-16761-8

Table 2.

Univariable and multivariable analysis of overall survival.

Variable	mOS (months)	Univariable		Multivariable
Variable	mOS (months)	HR [95% CI]	p	HR [95% CI]	p
Sex
Women	34	1.01 [0.43–2.40]	0.9792	1.18 [0.46–3.01]	0.7287
Men	45	1.01 [0.43–2.40]	0.9792	1.18 [0.46–3.01]	0.7287
Age
< 65 years	36	0.92 [0.39–2.17]	0.8365	1.01 [0.40–2.50]	0.9899
≥ 65 years	NR	0.92 [0.39–2.17]	0.8365	1.01 [0.40–2.50]	0.9899
Lauren histological type
Intestinal vs	NR	2.99 [1.25–7.12]	0.0303*	2.41 [0.76–7.60]	0.1350
Diffuse/Mixed	31	2.99 [1.25–7.12]	0.0303*	2.41 [0.76–7.60]	0.1350
(y)pT
0–2	NR	7.00 [2.94–16.63]	0.0017*	7.47 [1.72–32.48]	0.0076*
3–4	30	7.00 [2.94–16.63]	0.0017*	7.47 [1.72–32.48]	0.0076*
(y)pN
N−	45	5.25 [2.33–13.09]	0.0002*	6.18 [1.97–19.44]	0.0019*
N+	30	5.25 [2.33–13.09]	0.0002*	6.18 [1.97–19.44]	0.0019*
(y)pM
0	45	1.85 [0.55–6.24]	0.1371	1.35 [0.40–4.51]	0.6264
1	30	1.85 [0.55–6.24]	0.1371	1.35 [0.40–4.51]	0.6264
(y)pTNM stage
0-IIIA	45	3.29 [1.33–8.18]	0.0027*	3.06 [1.21–7.76]	0.0191*
IIIB-IV	29	3.29 [1.33–8.18]	0.0027*	3.06 [1.21–7.76]	0.0191*
Histopatological grading
G2	34	0.37 [0.12–1.16]	0.1688	0.43 [0.09–1.96]	0.2763
G3	NR
Neoadjuvant chemotherapy
Yes	50	2.13 [0.81–5.64]	0.1763	3.35 [0.71–15.84]	0.1293
No	34	2.13 [0.81–5.64]	0.1763	3.35 [0.71–15.84]	0.1293
Tumour Regression Grade
1, 2	NR	4.22 [1.59–11.14]	0.0327*	2.90 [0.62–13.66]	0.1801
3, 4	30	4.22 [1.59–11.14]	0.0327*	2.90 [0.62–13.66]	0.1801
Type of gastrectomy
Proximal, Distal vs	NR	2.00 [0.84–4.69]	0.1022	1.69 [063–4.51]	0.2994
Total	32	2.00 [0.84–4.69]	0.1022	1.69 [063–4.51]	0.2994
Cytology
Negative	36	0.84 [0.22–3.29]	0.7595	0.27 [0.03–2.40]	0.2426
Positive	50	0.84 [0.22–3.29]	0.7595	0.27 [0.03–2.40]	0.2426
OSNA assay
Negative	45	3.45 [0.95–12.48]	0.0030*	3.10 [1.22–8.54]	0.0298*
Positive	19	3.45 [0.95–12.48]	0.0030*	3.10 [1.22–8.54]	0.0298*

Reference (control) variables were underlined.

*Statistically significant results. mOS median overall survival, HR hazard ratio, CI confidence interval, (y)pT (post neoadjuvant) pathological primary tumour stage, (y)pN (post neoadjuvant) pathological nodal stage, (y)pM (post neoadjuvant) pathological distant metastasis stage, TNM tumour, node, metastasis, G grade, OSNA One-Step Nucleic Acid Amplification Assay, NR not reached.